Your session is about to expire
← Back to Search
Alvelestat for Alpha-1 Antitrypsin Deficiency (ATALANTa Trial)
ATALANTa Trial Summary
This trial is testing a new drug to treat a rare lung disease. The disease is caused by a mutation in the AAT gene. The trial will last 12 weeks and will test the safety and effectiveness of the drug.
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease
ATALANTa Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ATALANTa Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with lung diseases other than COPD, such as interstitial lung diseases, cystic fibrosis, or bronchiectasis, as determined by the doctor.You have other health conditions or abnormal lab results that could affect the study results, your safety, or your ability to follow the study instructions.You have had a significant worsening of your lung disease that required taking oral steroids and/or antibiotics within the past 4 weeks.
- Group 1: Alvelestat (MPH966)
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there a multitude of hospitals conducting this research endeavor in the US?
"Presently, this research endeavour is occurring at 10 distinct sites. These locales are situated in Philadelphia, Tyler and Los Angeles alongside an additional 10 cities. It is prudent to select the centre closest to you for convenience if recruited into the study."
How many participants are engaging in this clinical trial?
"Affirmative. Clinical trials dot gov data indicates that this medical trial, initially posted on April 8th 2019, is still recruiting participants. 66 patients are being sought across 10 different locations."
Is enrollment for this research initiative still available?
"Per the clinicaltrials.gov database, this research project is actively searching for participants and was recently updated on August 23rd 2022 after being first posted on April 8th 2019."
Does my profile meet the criteria to participate in this clinical experiment?
"This trial is seeking 66 adults aged between 18 and 80 who have alpha 1-antitrypsin. The primary criteria for participation include the capacity to provide informed consent, their age range, a confirmed diagnosis of AATD within certain parameters, an FEV1 score over 25% predicted, and if applicable contraceptive measures being undertaken by either male or female participants."
Has a study like this ever been implemented previously?
"Research into the drug Alvelestat (MPH966) commenced in 2019. Mereo BioPharma spearheaded an initial trial involving 66 patients that year, which saw the medication pass its Phase 2 regulatory assessment. Currently, only one live study of Alvelestat (MPH966) is taking place and it is sponsored by Mereo BioPharma."
Has Alvelestat (MPH966) been previously tested in other clinical trials?
"Currently, Alvelestat (MPH966) is the focus of one ongoing medical study, with no trials presently in Phase 3. Primarily based within Cleveland, Ohio; 10 different sites are conducting clinical trials on this drug."
Does this clinical investigation permit the enrollment of octogenarians?
"According to the trial's outlined qualifications, candidates should be between 18 and 80 years of age. For those younger than 18 or older than 65, alternate trials may apply - 2 for minors and 36 for senior citizens."
Has Alvelestat (MPH966) been granted regulatory authorization?
"The safety rating for Alvelestat (MPH966) is a 2 on the Power scale, as this clinical trial only has preliminary data suggesting its safety rather than any empirical evidence of efficacy."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger